CN108358848A - A kind of synthetic method of bendamustine hydrochloride intermediate - Google Patents

A kind of synthetic method of bendamustine hydrochloride intermediate Download PDF

Info

Publication number
CN108358848A
CN108358848A CN201810038788.3A CN201810038788A CN108358848A CN 108358848 A CN108358848 A CN 108358848A CN 201810038788 A CN201810038788 A CN 201810038788A CN 108358848 A CN108358848 A CN 108358848A
Authority
CN
China
Prior art keywords
bendamustine hydrochloride
synthetic method
reaction
nitroanilines
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810038788.3A
Other languages
Chinese (zh)
Inventor
魏海洋
徐成浩
皱培欢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WUJIANG XINKAI MEDICAL TECHNOLOGY Co Ltd
Original Assignee
WUJIANG XINKAI MEDICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUJIANG XINKAI MEDICAL TECHNOLOGY Co Ltd filed Critical WUJIANG XINKAI MEDICAL TECHNOLOGY Co Ltd
Priority to CN201810038788.3A priority Critical patent/CN108358848A/en
Publication of CN108358848A publication Critical patent/CN108358848A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a kind of synthetic methods of bendamustine hydrochloride intermediate; using 2 chlorine, 5 nitroaniline as raw material; acylation reaction is carried out with glutaric anhydride; obtain intermediate 1; the intermediate 1 is subjected to substitution reaction in methylamine water solution, intermediate 2 is made; the intermediate 2 and ethyl alcohol are subjected to cyclization, esterification under the conditions of sulfuric acid, obtain 1 methyl of target product, 5 nitro 1H benzimidazoles, 2 ethyl butyrate.Method provided by the invention has the characteristics that simple synthetic route, high income, wastewater flow rate are few.

Description

A kind of synthetic method of bendamustine hydrochloride intermediate
Technical field
The present invention relates to a kind of synthetic methods of bendamustine hydrochloride intermediate, belong to chemosynthesis technical field.
Background technology
1- methyl-5-nitros -1H- benzimidazolyl-2 radicals-ethyl butyrate is the important intermediate of bendamustine hydrochloride.Hydrochloric acid Bendamustine is a kind of bifunctional alkylating agents, has antitumor action.2003, with trade name Ribomustine in Germany Listing, for treating breast cancer, chronic lymphocytic leukemia, in the bendamustine hydrochloride trade name of U.S.'s listing Treanda proposes application for quotation by Cephalon companies, and obtains FDA approvals by preferential examination and approval procedures.In March, 2008, FDA ratifies bendamustine hydrochloride for treating chronic lymphocytic leukemia (CLL) first.October in the same year, FDA ratify again 2nd idicatio of the medicine, i.e., in Rituximab (rituximab, Mabthera) or the mistake of Regimen Chemotherapy containing Rituximab Cheng Zhong, or treat in 6 months, inertia B cell non-Hodgkin lymphoma (NHL) patient that the state of an illness is still in progress.Hydrochloric acid benzene reaches Mo Siting plasma protein binding rates are 94%~96%, and data show that the medicine generally will not be mutual with other high protein combination drugs Displacement.Bendamustine hydrochloride average steady state distribution volume is about 25L, and whole blood/plasma concentration ratio is 0.84~0.86.Hydrochloric acid Bendamustine is mainly metabolized by hydrolysis, and the lower metabolite of cytotoxicity is formed simultaneously.1- methyl -5- nitre The synthesis of base -1H- benzimidazolyl-2 radicals-ethyl butyrate is mainly made by the synthetic route of patent CN101948436, and synthetic route is such as Under:
The route is four-step reaction, which is to use vulcanized sodium selective reduction nitro in second step reaction For amino, a large amount of vulcanized sodium waste water is will produce in post-processing, it is more serious to the damage ratio of environment, and the selectivity restored is not Height, patent CN101948436 yields are 73.5%.Route is there is also the relatively low problem of yield, and total recovery is in 44%-55%.
Invention content
The few hydrochloric acid of simple, high income that the technical problem to be solved by the invention is to provide a kind of synthetic routes, wastewater flow rate The synthetic method of bendamustine intermediate.
In order to solve the above technical problems, the technical solution adopted by the present invention is:
A kind of synthetic method of bendamustine hydrochloride intermediate, using the chloro- 5- nitroanilines of 2- as raw material, with glutaric anhydride Acylation reaction is carried out, intermediate 1 is obtained, the intermediate 1 is carried out substitution reaction in methylamine water solution is made intermediate 2, will The intermediate 2 carries out cyclization, esterification with ethyl alcohol under the conditions of sulfuric acid, obtains target product 1- methyl-5-nitros -1H- Benzimidazolyl-2 radicals-ethyl butyrate, synthetic route are as follows:
It is 1 that the chloro- 5- nitroanilines of 2-, which react molar ratio with the glutaric anhydride,:1.
The chloro- 5- nitroanilines of 2- are 80 DEG C with the glutaric anhydride reaction temperature.
The chloro- 5- nitroanilines of 2- are 3h with the glutaric anhydride reaction time.
It is 4 that the methylamine, which reacts molar ratio with the chloro- 5- nitroanilines of the 2-,:1.
The reaction temperature of the substitution reaction is 50 DEG C.
The reaction time for stating substitution reaction is 3h.
The advantageous effect that the present invention is reached:The synthetic method route provided in the present invention is short, avoids using vulcanized sodium The step of reaction, greatly reduces the generation of waste water;Total recovery is increased to 79% by former route 44%-55%, improves reaction Yield shortens the production cycle, reduces cost.
Specific implementation mode
The invention will be further described below.Following embodiment is only used for clearly illustrating the technical side of the present invention Case, and not intended to limit the protection scope of the present invention.
Embodiment 1:
It takes the chloro- 5- nitroanilines of 51.6g 2- to be added in there-necked flask, 500ml toluene is added, 36g penta is added at room temperature Dicarboxylic anhydride is heated to 80 DEG C and reacts 3 hours, be cooled to room temperature, filters, and filter cake is dried at 70 DEG C, obtains yellow solid intermediate 1 45g, yield 95%.
Above-mentioned obtained intermediate 1 is added in 40% methylamine water solutions of 150ml, 50 DEG C is heated to and reacts 3 hours, it is cold But yellow solid is precipitated with 2N hydrochloric acid tune PH=4-5 to room temperature, after stirring 1h, filtering, filter cake is eluted with toluene, 70 DEG C of bakings It is dry, obtain 2 40.5g yields 91.7% of yellow solid intermediate.
Above-mentioned obtained intermediate 2 is added in there-necked flask, is added in 365ml absolute ethyl alcohols, lower dropwise addition 12ml is stirred 98% concentrated sulfuric acid drips and is heated to 80 DEG C of reflux 3h, is cooled to 45-50 DEG C, reaction solution is poured into unsaturated carbonate aqueous solutions of potassium In (500ml), a large amount of white solids are precipitated, filter, filter cake is washed to neutrality, and 70 DEG C of drying obtain white powder 1- methyl- 5- nitros -1H- benzimidazolyl-2 radicals-ethyl butyrate 40g, yield 90.7%, purity 99.8%, fusing point:110-114℃.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art For member, without departing from the technical principles of the invention, several improvement and deformations can also be made, these improvement and deformations Also it should be regarded as protection scope of the present invention.

Claims (7)

1. a kind of synthetic method of bendamustine hydrochloride intermediate, which is characterized in that using the chloro- 5- nitroanilines of 2- as raw material, Acylation reaction is carried out with glutaric anhydride, obtains intermediate 1, the intermediate 1 is carried out substitution reaction in methylamine water solution to be made The intermediate 2 and ethyl alcohol under the conditions of sulfuric acid are carried out cyclization, esterification, obtain target product 1- methyl-by intermediate 2 5- nitros -1H- benzimidazolyl-2 radicals-ethyl butyrate, synthetic route are as follows:
2. a kind of synthetic method of bendamustine hydrochloride intermediate as described in claim 1, which is characterized in that the 2- It is 1 that chloro- 5- nitroanilines, which react molar ratio with the glutaric anhydride,:1.
3. a kind of synthetic method of bendamustine hydrochloride intermediate as described in claim 1, which is characterized in that the 2- Chloro- 5- nitroanilines are 80 DEG C with the glutaric anhydride reaction temperature.
4. a kind of synthetic method of bendamustine hydrochloride intermediate as described in claim 1, which is characterized in that the 2- Chloro- 5- nitroanilines are 3h with the glutaric anhydride reaction time.
5. a kind of synthetic method of bendamustine hydrochloride intermediate as described in claim 1, which is characterized in that the methylamine It is 4 that molar ratio is reacted with the chloro- 5- nitroanilines of the 2-:1.
6. a kind of synthetic method of bendamustine hydrochloride intermediate as described in claim 1, which is characterized in that the substitution The reaction temperature of reaction is 50 DEG C.
7. a kind of synthetic method of bendamustine hydrochloride intermediate as described in claim 1, which is characterized in that the substitution The reaction time of reaction is 3h.
CN201810038788.3A 2018-01-16 2018-01-16 A kind of synthetic method of bendamustine hydrochloride intermediate Pending CN108358848A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810038788.3A CN108358848A (en) 2018-01-16 2018-01-16 A kind of synthetic method of bendamustine hydrochloride intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810038788.3A CN108358848A (en) 2018-01-16 2018-01-16 A kind of synthetic method of bendamustine hydrochloride intermediate

Publications (1)

Publication Number Publication Date
CN108358848A true CN108358848A (en) 2018-08-03

Family

ID=63006117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810038788.3A Pending CN108358848A (en) 2018-01-16 2018-01-16 A kind of synthetic method of bendamustine hydrochloride intermediate

Country Status (1)

Country Link
CN (1) CN108358848A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106363A2 (en) * 2003-05-30 2004-12-09 Css-Albachem Limited A tag for purification of peptides
CN101948437A (en) * 2010-06-28 2011-01-19 江苏奥赛康药业有限公司 Refining method of bendamustine hydrochloride
CN101948436A (en) * 2010-06-28 2011-01-19 江苏奥赛康药业有限公司 Method for preparing high-purity bendamustine hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106363A2 (en) * 2003-05-30 2004-12-09 Css-Albachem Limited A tag for purification of peptides
CN101948437A (en) * 2010-06-28 2011-01-19 江苏奥赛康药业有限公司 Refining method of bendamustine hydrochloride
CN101948436A (en) * 2010-06-28 2011-01-19 江苏奥赛康药业有限公司 Method for preparing high-purity bendamustine hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
高丽梅,等: "盐酸苯达莫司汀的合成", 《中国新药杂志》 *

Similar Documents

Publication Publication Date Title
CN105820110B (en) Mo Fanselin synthetic methods
CN104974072B (en) A kind of method for preparing Silodosin intermediate
CN107501237A (en) A kind of Apalutamide new synthetic method
CN105906628B (en) A kind of Li Gelieting preparation method
CN105884628B (en) The preparation method of 2,4- di-t-butyl -5- amino phenols
CN106366022A (en) Intermediate used for AZD9291 preparation, and preparation method and application thereof
CN102079737A (en) Method for preparing apigenin
CN102993121A (en) Synthetic method for preparing roxatidine acetate hydrochloride with high purity
CN107674035A (en) A kind of preparation, structure and the photoluminescent property of benzimidazole hydrochloride
CN104327129A (en) Method for preparing glucosamine hydrochloride by taking crab shells as raw materials
CN108358848A (en) A kind of synthetic method of bendamustine hydrochloride intermediate
CN108164577A (en) A kind of P1, P4- two(Uridine -5 '-tetraphosphate)The industrialized process for preparing of sodium salt
CN104496936B (en) A kind of preparation method of body of Pramipexole dihydrochloride
CN103396323B (en) Production method of bromhexine hydrochloride
CN102285924A (en) Synthesis method of benzimidazolone
CN102827052A (en) Method for synthesizing 3-hydroxy-azetidinehydrochloride
CN106518939B (en) Method for preparing Solithromycin compound
CN101575301B (en) Preparation method of 2-amino-5-chlorobenzamide
CN104530144B (en) Reactor and method for preparing glucosamine sulfate
CN107021930A (en) Synthesize 1H, 1`H(2,2` bisbenzimidazoles)The method of 5,5` diamines
CN103193619B (en) Method for synthesis of phenylacetic acid by carbonylation of benzyl chloride
CN102030693A (en) Acetylcysteine compound and novel method thereof
CN110294694A (en) A kind of improved preparation method of intermediate DAS of paratonere 177
CN101492413A (en) Fine purification method for carprofen
CN110028601A (en) A kind of beta-cyclodextrin derivative, preparation method and the method for preparing supermolecule vesica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180803

RJ01 Rejection of invention patent application after publication